15.0 Abstract: Molecular and Structural Biology Program The overarching goals of the Molecular and Structural Biology (MSB) Program of UMGCC are to elucidate molecular mechanisms and cellular processes that are altered in cancer and to encourage translation of these basic scientific findings toward the development of novel strategies for treating cancer. To achieve these goals, the program focuses on three themes: Theme 1: DNA repair and checkpoint signaling?characterizing defects in DNA repair and checkpoint signaling and understanding how these defects impact cancer development; Theme 2: Inappropriate gene expression?determining how defects in transcriptional and posttranscriptional processes lead to inappropriate regulation of protein expression in cancer; and Theme 3: Oncogenes and tumor suppressors?delineating how signaling pathways (i.e., oncogenic, tumor suppressor, etc.) are deregulated in cancer and identifying specific biomolecules that can be targeted to reverse these effects. The MSB Program has 50 members representing 16 academic departments and 6 schools of the University of Maryland. Members of the program conduct cancer-focused research that receives $6.78 million total annual funding, including $2.34 million from NCI and $3.58 million from other peer-reviewed sources. In addition, the MSB Program members receive over $0.86 million annually from non-peer-reviewed funding sources. Between January 2010 and December 2014, MSB members authored 664 cancer-related publications, of which 13 percent resulted from intraprogrammatic and 18 percent from interprogrammatic collaborations. Approximately 48 percent of the publications represent collaborations with external investigators. Research efforts by MSB faculty are supported by extensive use of the SBSS, FCSS, TLSS, PBSS, ISS, and BSS.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA134274-11
Application #
9537292
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
11
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Type
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Wang, Junxiang; Zhao, Liang; Ye, Yanfang et al. (2018) Adverse event detection by integrating twitter data and VAERS. J Biomed Semantics 9:19
Furusawa, Aki; Reiser, John; Sadashivaiah, Kavitha et al. (2018) Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy. J Immunother 41:53-63
Nathenson, Michael J; Conley, Anthony P; Sausville, Edward (2018) Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist 23:71-83
Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Exploring the effect of library preparation on RNA sequencing experiments. Genomics :
Nathenson, Michael J; Barysauskas, Constance M; Nathenson, Robert A et al. (2018) Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. World J Surg Oncol 16:203
Sallmyr, Annahita; Tomkinson, Alan E (2018) Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem 293:10536-10546
Kerr, Candace; Adhikary, Gautam; Grun, Daniel et al. (2018) Combination cisplatin and sulforaphane treatment reduces proliferation, invasion, and tumor formation in epidermal squamous cell carcinoma. Mol Carcinog 57:3-11
Connolly, Sean; Quasi-Woode, Devona; Waldron, Laura et al. (2018) Calcineurin Regulatory Subunit Calcium-Binding Domains Differentially Contribute to Calcineurin Signaling in Saccharomyces cerevisiae. Genetics 209:801-813
Pauza, C David; Liou, Mei-Ling; Lahusen, Tyler et al. (2018) Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local. Front Immunol 9:1305
Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients. Cancer Res 78:4411-4423

Showing the most recent 10 out of 257 publications